Sinclair IS Pharma has signed a deal with Israeli major Teva Pharmaceutical Industries which will see the latter license the UK firm’s for Sinclair’s oncology product episil.
Under the terms of the agreement, Teva will have the exclusive commercialisation rights for episil in Germany, Spain, Poland, Switzerland and the Czech Republic. The product spray is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy.
Chris Sponner, chief executive of the London-headquartered firm, said a key part of the rationale behind Sinclair’s recent merger with IS Pharma “was to broaden the sales reach of the IS portfolio through Sinclair’s direct country and regional operations”. He added that “this is the first in what we expect to be a number of marketing and co-marketing partnerships”.
Sinclair will retain an option to co-promote epistle, which creates a strong bioadhesive film that protects sore areas of the mouth providing pain reduction of at least eight hours, in Germany and Spain where it has its own direct sales force. Financial details of the license deal have not been released.
